checkAd
    Startseite > Aktien > Gilead Sciences > Nachrichten
    Gilead Sciences Aktie
    58,80
     
    EUR
    +0,27 %
    +0,16 EUR
    Letzter Kurs 10:08:21 Tradegate
    58,58
     
    EUR
    260 STK
    Geldkurs 10:09:57
    58,80
     
    EUR
    260 STK
    Briefkurs 10:09:57
    ISIN: US3755581036 · WKN: 885823 · SYM: GIS · USA ·

    Neueste Nachrichten

    Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
    06.06.24 · Business Wire (engl.) · Gilead Sciences
    Biotech Report: Evotec (EVT) und Qiagen (QIA) mit Kursgewinnen
    05.06.24 · Shareribs · EvotecAnzeige
    Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
    05.06.24 · Business Wire (engl.) · Gilead Sciences
    Biotech Report: Biontech (22UA) und Evotec (EVT) legen zu
    03.06.24 · Shareribs · AmgenAnzeige
    Kite’s Tecartus Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    03.06.24 · Business Wire (engl.) · Gilead Sciences
    Encouraging New Data Presented on Kite’s Yescarta for Relapsed/Refractory Central Nervous System Lymphoma
    03.06.24 · Business Wire (engl.) · Gilead Sciences
    Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
    02.06.24 · Business Wire (engl.) · Gilead Sciences
    Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
    02.06.24 · Business Wire (engl.) · Gilead Sciences
    Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
    01.06.24 · Business Wire (engl.) · Gilead Sciences
    Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
    01.06.24 · Business Wire (engl.) · Gilead Sciences
    EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
    31.05.24 · Business Wire (engl.) · Gilead Sciences
    Gilead Provides Update on Phase 3 TROPiCS-04 Study
    30.05.24 · Business Wire (engl.) · Gilead Sciences